Onyx Seeks Suitors After Rejecting Amgen’s Bid

Onyx Seeks Suitors After Rejecting Amgen’s Bid Play

July 1 (Bloomberg) -- Onyx Pharmaceuticals, the maker of the cancer drug Nexavar, said it is in contact with other possible acquirers after rejecting an unsolicited $120-a-share cash takeover bid from Amgen Onyx shares surged. Dominic Chu reports on Bloomberg Television's "Market Makers." (Source: Bloomberg)

blog comments powered by Disqus